Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine combination for relapsed AML after allo-SCT
NCT01369368Phase 2Unknown
- Sponsor
- University of Bergen
- Start
- Aug 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, valproic acid, tretinoin, hydroxyurea in acute myeloid leukemia (AML), sponsored by University of Bergen. Status: unknown.
02
Drugs
azacitidinevalproic acidtretinoinhydroxyurea
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01369368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01369368.